Table 3. Adverse events or intercurrent illness throughout treatment with weekly pegIFN-α-2a (135 µg) plus oral Ribavirin (400 mg twice daily); n = 58 patients.
| Total | Grade 1 -2 | Grade 3 | Grade 4 | |
| no. (%) | no. (%) | no. (%) | no. (%) | |
| Flu-like syndrome | 30 (51.7) | 27 (46.5) | 3 (5.1) | |
| Myalgia | 9 (15.5) | 8 (13.7) | 1 (1.7) | |
| Fatigue | 28 (48.2) | 28 (48.2) | ||
| Unintentional weight loss ≥10% | 14 (24.1) | 14 (24.1) | ||
| Anorexia | 23 (39.6) | 23 (39.6) | ||
| Depression | 14 (24.1) | 13 (22.4) | 1 (1.7) | |
| Irritability - nervousness | 12 (20.6) | 11 (18.9) | 1 (1.7) | |
| Insomnia | 11 (18.9) | 10 (16.7) | 1 (1.7) | |
| Nausea – vomiting | 15 (25.8) | 15 (25.8) | ||
| Anemia | 7 (12.0) | 6 (10.3) | 1 (1.7) | |
| Neutropenia | 21 (36.2) | 18 (31.0) | 3 (5.1) | |
| Thrombocytopenia | 10 (18.3) | 10 (18.3) | ||
| Other | ||||
| - Subarachnoid hemorrhage (death) | 1 (1.7) | 1 (1.7) | ||
| - Neuroleptic malignant syndrome (death) | 1 (1.7) | 1 (1.7) | ||
| - Sudden death | 1 (1.7) | 1 (1.7) | ||
| - Pneumococcal pneumonia | 1 (1.7) | 1 (1.7) | ||
| - Esophageal stenosis (relapse) | 1 (1.7) | 1 (1.7) | ||
| - Thrush | 1 (1.7) | 1 (1.7) | ||
| - Deep vein thrombosis | 1 (1.7) | 1 (1.7) | ||
| - Cough | 2 (3.4) | 2 (3.4) | ||
| - Headache | 2 (3.4) | 2 (3.4) | ||
| - Dizziness | 1 (1.7) | 1 (1.7) | ||
| - Injection site erythema | 1 (1.7) | 1 (1.7) |